Multi-parametric MRI for Therapeutic Response Prediction in Rectal Cancer

Not Applicable

Recruiting

• Conditions: Rectal Cancer; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12616001690448
• Lead Sponsor: Dr Trang Pham

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-12-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

1.Age greater than 18
2.Stage II or III rectal adenocarcinoma, defined as T3 - T4 and/or node positive disease (N1-2), without distant metastatic disease (M0)
3.No evidence of metastatic disease on CT chest/abdomen/pelvis
4.Undergoing treatment algorithm consisting of neoadjuvant chemoradiotherapy (radiotherapy 50.4Gy in 28 fractions concurrent with infusional 5-fluorouracil or oral capecitabine) followed by surgery at 6 to 12 weeks post chemoradiotherapy.

Exclusion Criteria

1.Other malignancy
2.Active inflammatory bowel disease
3.On concurrent high-dose corticosteroids (the equivalent of 50mg prednisone daily)
4.Inability to have MRI due to:
a. Implanted magnetic metal eg. Intraocular metal
b. Pacemaker / Implantable defibrillator
c. Extreme claustrophobia.

Study & Design

• Study Type: Observational
• Study Design: Not specified